Drug
Gtx-758 clinical trials
Also written GTx-758.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
- GTx-758
- 2
Studies by the year they started
4 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2011 | 3 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
GTx (4)
Studies
Open first, then newest update. How each study uses gtx-758 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Phase II, Dose Finding Study of GTx-758TerminatedPhase 2GTxNCT01393119Written as GTx-758
- GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate CancerTerminatedPhase 2GTxNCT01420861Written as GTx-758
- Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate CancerTerminatedPhase 2GTxNCT01326312Written as GTx-758 1000mg
- Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate CancerCompletedPhase 2GTxNCT01615120Written as GTx-758 125 mg
Codes
What other systems call gtx-758 · ClinicalTrials.gg INT000353
- UNII (FDA) 406GR1485ZGTX-758One source FDA
- NCI Thesaurus C96432Estrogen Receptor Agonist GTx-758One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 406GR1485Z | GTX-758 | One source FDA |
| NCI Thesaurus | C96432 | Estrogen Receptor Agonist GTx-758 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.